#United States #Los Angeles #Securities Fraud #Legal Action #Regeneron Pharmaceuticals

New Opportunity for Investors in Regeneron Pharmaceuticals

Recently, investors who suffered financial setbacks linked to Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have been given a critical opportunity to step forward in a pending legal battle. The Los Angeles-based Law Offices of Frank R. Cruz have announced that these investors can take a lead role in a class action lawsuit focusing on alleged securities fraud against the company. This lawsuit revolves around allegations stating that between November 2, 2023, and October 30, 2024, Regeneron failed to disclose damaging information that misled investors about the company's operations and financial health.

What Are the Allegations?

The core of the lawsuit highlights several key points of misconduct. Investors claim that Regeneron engaged in practices that falsely inflated the sales figures of its primary product, Eylea, making monetary gains appear more substantial than they actually were. Specific allegations include the following:

1. Payment of Credit Card Fees: It was claimed that Regeneron paid fees to distributors under the condition that they would not raise credit card charges for Eylea customers.
2. Price Subsidies: These undisclosed payments essentially subsidized purchase prices for customers using credit cards, inadvertently lowering Eylea's market price.
3. Misleading Sales Figures: As a result of these practices, Regeneron could boost its reported sales for Eylea, thus providing a misleading picture of its financial performance to stakeholders.
4. Violation of False Claims Act: By not reporting these payments properly, Regeneron allegedly violated the False Claims Act, which governs the integrity of federal funds and regulatory compliance.
5. Materially Misleading Statements: Statements made by Regeneron about its business operations and future prospects are said to have lacked a solid foundation due to these undisclosed practices, leading to investor losses.

How Can Affected Investors Participate?

For investors who have faced losses related to Regeneron, this is a crucial point in the timeline of the lawsuit. The law firm encourages affected individuals to take action as the deadline for lead plaintiff applications approaches on March 10, 2025. Interested investors are urged to contact the Law Offices of Frank R. Cruz for guidance on how to participate in the ongoing litigation.

Steps for Investors to Consider

To join the class action or gain more insights into the lawsuit, affected investors can take the following steps:

• - Reach out to Legal Counsel: Contact the Law Offices of Frank R. Cruz via email or phone for additional information.
• - Email Requirements: If communicating via email, ensure to include your contact information and details regarding your stock purchases in Regeneron.
• - No Immediate Action Required: Investors do not have to take immediate action but retaining legal counsel is advisable to safeguard their rights.

Conclusion

This lawsuit represents a significant opportunity for investors who believe they have been wronged by Regeneron's alleged misconduct. The unfolding legal case emphasizes the importance of transparency and accountability in the pharmaceutical industry, and it is a pivotal moment for those who have invested in Regeneron Pharmaceuticals. Stakeholders are encouraged to stay informed and act promptly to protect their financial interests in this ongoing legal matter.